Our Recommendation
Muso Health is a top‑tier choice for funders who prioritize rigorous evidence on ultimate health outcomes—especially child survival—combined with serious government partnership and system redesign. Their proactive care model has unusually strong counterfactual evidence for reducing under‑five mortality, but maternal and broader wellbeing outcomes remain less fully measured, and most intermediate gains outside of child treatment and immunization are not yet backed by experimental counterfactuals. Muso fits our framework very well on theory of change, implementation fidelity, and serious use of research to drive strategy, with clear room for growth in measuring non‑mortality ultimate outcomes and equity effects.
Muso Health's Fierce Certification score is 120/100 based on our criteria:
✔ Has Ultimate Outcome Goals (50 pts)
✔ Measures Intermediate Outcomes (10 pts)
✔ Measures Ultimate Outcomes (15 pts)
✔ Shows Continual Learning & Adaptation (25 pts)
✔ Measures Intermediate Counterfactual (10 pts)
✔ Measures Ultimate Counterfactual (10 pts)
The Social Problem
Muso focuses on the lethal delay between the onset of illness and effective treatment for mothers and children, especially in poor communities in Mali and Côte d’Ivoire. Conventional health systems wait for patients to arrive at facilities, but many families face geographic, financial, and systemic barriers that mean children and pregnant women either arrive too late or not at all, driving preventable mortality. This delay both reflects and reinforces broader injustices: under‑resourced clinics, weak community health systems, inequitable access for the poorest households, and slow progress toward universal health coverage.
The Solution
Muso’s solution is a three‑step Rapid/Proactive Care model that reorganizes health systems around speed and universality: proactive Community Health Worker (CHW) doorstep care, redesigned clinics that can handle patients quickly and well, and national‑level policy and financing changes. CHWs search for and treat patients at home, clinics are coached and supported to deliver high‑quality care without fees at point of service, and Muso partners with governments to integrate these approaches into national systems through technical assistance and policy advocacy. The theory of change is that curing delay by pushing the system to find patients fast and treat them effectively will reduce under‑five and maternal mortality and build a path toward universal, equitable health coverage.
Key Outputs
Key outputs that frame Muso’s work:
- Geographic and population coverage: Muso operates across multiple sites in Mali and has expanded to Côte d’Ivoire, supporting both direct service delivery and government‑run programs.
- CHW support systems: Thousands of CHWs are supported through the 360° Supervision model, using dashboards and structured supervision to manage speed, quality, and coverage.
- Cost and efficiency metrics: Costing analyses show a reduction in cost per patient served at Rapid Care sites from $29 to $22 between 2023 and 2024 (23% reduction), with further decreases in cost per person served in early 2025.
- Research portfolio: Muso’s research page highlights multiple studies, including the landmark Pro‑CCM evaluation and ongoing operational research in 29+ sites in Côte d’Ivoire focusing on immunization and UHC.
These outputs show a blend of direct service, systems‑building, and embedded research that is unusual among community‑health implementers.
Key Intermediate Outcomes
Intermediate outcomes with measurement (and counterfactuals where present):
- Speed of treatment for febrile children: In the Pro‑CCM study, the share of children receiving effective antimalarial treatment within 24 hours of symptom onset increased markedly over the three‑year intervention, as measured through repeated randomized household surveys.
- CHW performance (speed, quality, coverage): The 360° Supervision model study found that CHWs under this model improved on these three metrics over time, using routine performance data and supervisory observation.
- Immunization coverage: A multi‑district immunization learning collaboration with government used routine data to show increased immunization coverage in Muso‑supported areas over time.
- Efficiency of care delivery: Costing analyses demonstrate lower cost per patient/person served while maintaining or increasing service volumes, reflecting efficiency gains rather than service cuts.
These are classic intermediate outcomes (access, coverage, and service performance) supported by a mix of before/after and embedded research designs, with Pro‑CCM providing the strongest quasi‑counterfactual signal.
Key Ultimate Outcomes
Ultimate outcomes as Muso currently measures them:
- Under‑five mortality: The Pro‑CCM evaluation in Mali found that, after three years of Muso’s intervention, the hazard of under‑five mortality in the intervention area was one tenth of baseline (HR 0.10, p<0.0001), representing a dramatic reduction in child deaths.
- Broader survival and wellbeing outcomes: Muso’s global‑impact framing and advocacy emphasize ending preventable maternal and child deaths and advancing UHC, but maternal mortality, neonatal mortality disaggregated outcomes, and wellbeing metrics (e.g., mental health, financial protection) are not yet reported with the same level of rigor.
So far, Muso’s clearest ultimate‑outcome evidence is on child survival, with other ultimate wellbeing outcomes still in the “important, but not yet measured as rigorously” category.
Continual Learning & Adaptation
Muso is highly aligned with our feedback‑loop ideal:
- Embedded research model: Their stated theory of change “begins with proactive health care,” “builds off embedded research designed to test our strategies,” and leads to technical assistance and policy change, showing research is built into the core model rather than bolted on.
- Real‑time learning systems: Muso uses CHW and clinic data dashboards to continuously monitor speed, quality, and coverage, and supervisors tailor support based on each CHW’s performance “fingerprint.”
- Policy and program adaptation: Muso works with governments to evaluate and adapt models (e.g., 29 operational research sites in Côte d’Ivoire, immunization coverage workshop), using findings to decide whether and how to integrate Rapid Care and 360° Supervision into national systems.
Muso is unusually strong on linking intermediate and ultimate outcomes with counterfactuals, and on using that learning to influence both their own practice and national policy while still having opportunities to expand measurement beyond mortality into broader wellbeing and equity outcomes.
Written by
